Swisher, Elizabeth M <br/><br/>
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.  [electronic resource] 

 -  The Lancet. Oncology  01 2017 
 - 75-87 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(16)30559-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--pharmacology<br/>BRCA1 Protein--genetics<br/>BRCA2 Protein--genetics<br/>Carcinoma, Ovarian Epithelial<br/>Drug Resistance, Neoplasm--drug effects<br/>Fallopian Tube Neoplasms--drug therapy<br/>Female<br/>Follow-Up Studies<br/>Germ-Line Mutation--genetics<br/>Humans<br/>Indoles--therapeutic use<br/>International Agencies<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasm Staging<br/>Neoplasms, Glandular and Epithelial--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Peritoneal Neoplasms--drug therapy<br/>Platinum--pharmacology<br/>Poly(ADP-ribose) Polymerase Inhibitors--therapeutic use<br/>Poly(ADP-ribose) Polymerases--chemistry<br/>Prognosis<br/>Prospective Studies<br/>Salvage Therapy<br/>Survival Rate